Comparative Analysis Of Effectiveness And Safety Between Metformin Monotherapy And The Combined Use Of Metformin With Vildagliptin In Individuals Diagnosed With Type 2 Diabetes Mellitus.
Article Sidebar
Main Article Content
Abstract
Background: Diabetes mellitus is a heterogeneous chronic metabolic disorder principally characterized by persistent hyperglycemia resulting from defects in insulin action and/or insulin secretion. In course of time, prolonged hyperglycemia and associated metabolic aberrations result in tissue toxicity manifested as accelerated atherosclerosis and neuropathy leading to a variety of vascular, neurological, and focal complications
Aim and Objective: The aim of this study is to evaluate the efficacy and safety of metformin with combination of metformin and vildagliptin in patients with Type 2 diabetes mellitus.
Materials and Methods: This is a longitudinal interventional study. A total of 100 patients were enrolled in the study. Those patients who were already on metformin 500 mg and 850 mg bid with poor glycemic control were included in the study. These 100 patients were divided into two groups each consisting of 50 patients. Group A patients received metformin 500 mg bid and metformin 850 mg bid. Group B patients received combination of metformin with vildagliptin 50/500 mg bid and metformin 50/850 mg bid. The total period of the study was 3 months.
Results: After 3 months of treatment, both the groups caused a significant decline in blood glucose levels both fasting blood sugar (FBS) as well as postprandial blood sugar (PPBS) levels. There was a significant difference between the two groups in reducing the FBS levels and PPBS. Hemoglobin A1C (HbA1c) was also reduced significantly in both groups at 12 weeks. After 3 months of therapy, there was a reduction in HbA1C in B group. The reduction of HbA1C was not statistically significant between the two groups. Adverse effects were more with metformin group at the end of 3 months therapy. There was a significant difference in the incidence of adverse effects between both the groups.
Conclusions: Vildagliptin and metformin combination provided better efficacy comparable to that of metformin and resulted in better adverse effect profile with lower risks of hypoglycemia and weight gain
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3:e442.
World Health Organization. Diabetes. Factsheet. Geneva: WHO; 2012 Available from: http://www.who.int/mediacentre/ factsheets/fs312/en/index.html. [Last cited on 2013 Jun 08]; [Last updated on 2017 Oct 12].
American Diabetes Association. Standards of medical care in diabetes-2017. Diabetes Care 2017; 40 Suppl 1:S6-S10.
Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase- 4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 2078–2084.
Azuma K, Radikova Z, Mancino J et al. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 2008; 93: 459–464.
Balas B, Baig MR, Watson C et al. The dipeptidyl peptidase iv inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007; 92: 1249–1255.
Mari A, Sallas WM, He YL et al. Vildagliptin, a dipeptidyl peptidase-iv inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 4888–4894.
Rosenstock J, Foley JE, Rendell M et al. Effects of the dipeptidyl peptidase-iv inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 2008; 31: 30–35.
Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple- dose study. Horm Metab Res 2007; 39: 218–223.
Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007; 76: 132–138.
Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in hba(1c) over 1 year in drug-naive patients with type 2 diabetes. Diabet Med 2007; 24: 955–961.
Scherbaum WA, Schweizer A, Mari A et al. Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008; 10: 675–682.
Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30: 890–895.
Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2008; 10: 82–90.
Mohan V, Zargar A, Chawla M, Joshi A, Ayyagari U, Sethi B, Gaurav K, Patted URH, Bhagat SV, Mane AI. Efficacy of a Combination of Metformin and Vildagliptin in Comparison to Metformin Alone in Type 2 Diabetes Mellitus: A Multicentre, Retrospective, Real-World Evidence Study. Diabetes Metab Syndr Obes. 2021;14:2925-2933
Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with Type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30:890-5.
Pan C, Xing X, Han P, Zheng S, Ma J, Liu J, et al. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with Type 2 diabetes mellitus. Diabetes Obes Metab. 2012;14:737-44.
Chatterjee S, Chatterjee S. Glycemic effects of vildagliptin and metformin combination therapy in Indian patients with Type 2 diabetes: An observational study. J Diabetes 2014;6:237-42.
Matthewes DR, Dejager S, Ahren B, GFonseca V, Ferrannini E, Cuturier A, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimeperide, with no weight gain: Results from a 2-year study. Horm Metab Res 2009;41:368-73.
Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S. Improved glycaemic control by addition of glimepiride to metformin monotherapy in Type 2 diabetic patients. Diabet Med 2001; 18:828-34.
Wang M, Gao F, Xue YM, Han YJ, Fu XJ, He FY, et al. Effect of short-term intensive therapy with glimepiride and metformin in newly diagnosed Type 2 diabetic patients. Nan Fang Yi Ke Da Xue Xue Bao 2011;31:564-6.
Pareek A, Chandurkar NB, Salkar HR, Borkar MS, Tiwari D. Evaluation of efficacy and tolerability of glimepiride and metformin combination: A multicentric study in patients with Type-2 diabetes mellitus, uncontrolled on monotherapy with sulfonylurea or metformin. Am J Ther 2013; 20:41-7.
Ved P, Shah S. Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with Type 2 diabetes mellitus. Indian J Endocrinol Metab 2012;16 Suppl 1:S110-3